At a glance
ClinicalIndex Comparison RecordN/ACompleted· 36 enrolled
Drug / intervention
Customized Adherence Enhancement for Schizophrenia (CAE-S) +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective 12-week Randomized Controlled Trial (RCT) of Remotely- Delivered Customized Adherence Enhancement for Poorly Adherent Individuals With Schizophrenia (CAE-S) vs Enhanced Treatment as Usual (eTAU)
University Hospitals Cleveland Medical Center·interventional·Posted Sep 29, 2023·Updated Nov 18, 2025
In Brief
A clinical study evaluating Customized Adherence Enhancement for Schizophrenia (CAE-S) and Enhanced Treatment as Usual (eTAU) for Schizophrenia. Completed, enrolled 36 participants across 1 site.
Detailed Summary
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
202420252026
First PostedSep 2023
Enrollment StartJan 2024
Primary CompletionAug 2025
TodayJul 2026
First PostedSep 29, 2023
Enrollment StartJan 16, 2024
Primary CompletionAug 9, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 2.8 years ago
Interventions
Customized Adherence Enhancement for Schizophrenia (CAE-S)behavioral
6-session series spaced out over approximately 6-10 weeks
Enhanced Treatment as Usual (eTAU)other
eTAU participants will view a pre-taped series of 6 videos